The cliff is closer than the deck admits, and the way to check is the grant date. Novo Nordisk holds GLP-1 derivative grants including US10392428B2, "GLP-1 derivatives and uses thereof" (issued August 27, 2019), and US10308700B2, "GLP-1 derivatives" (issued June 4, 2019). Both carry C07K 14/605 classifications — the peptide-composition class — which means they reach the molecule itself, not merely a use.
Here is the teardown logic. Composition-of-matter claims are the strongest IP a peptide franchise can hold, but their term is fixed by the priority date, not the issue date. A 2019 grant typically traces to a filing years earlier, so the protective window on these specific members is shorter from today than the franchise's newest filings. For a financing or M&A model, that is the difference between cash flows defensible into the next decade and cash flows facing biosimilar or follow-on entry sooner.
Disclosed, not promised: the exclusivity math is a stack, not a single date. A franchise layers composition grants, formulation grants, device patents, and method-of-use claims, each with its own expiry. The earliest-expiring claim that a competitor must clear sets the practical cliff for that route of entry. So the question a deals desk asks is not "when does the franchise expire" but "which claim is the load-bearing one for the entry path a challenger would take."
What the grant cannot tell you: whether a patent-term extension or pediatric exclusivity lengthens the runway, or whether a challenger's design-around lands outside the claims entirely. Those are document-dependent facts that live in the prosecution history and the regulatory record, not in the headline title. Anyone quoting a clean "loses exclusivity in year X" number without naming the controlling claim is estimating.
The takeaway for the business reader: when a franchise's value is debated, pull the underlying composition grants and read their dates. Novo Nordisk's GLP-1 derivative patents are real, strong, and — for the 2019 members — aging. The franchise narrative and the exclusivity cliff are the same story told from two ends of the patent term.